1. 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. (September 2015) Authors: Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.; Van Cutsem, E.; Tesselaar, M.E.T.; Shimada, Y.; Oh, D.Y.; Strosberg, J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗